Eli Lilly and Company (LLY) Tuesday announced that the U.S. Food and Drug Administration's Advisory Committee will convene a meeting on Donanemab for early symptomatic Alzheimer's disease.
The Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) will convene a meeting on Monday, June 10, 2024, to discuss Donanemab, which Eli Lilly has submitted for the treatment of early symptomatic Alzheimer's disease. The open public hearing portion of the meeting will be conducted virtually.
The Phase 3 study submitted as part of this application, TRAILBLAZER-ALZ 2, is a double-blind, placebo-controlled study to evaluate the safety and efficacy of Donanemab in participants ages 60-85 years with early symptomatic Alzheimer's disease with the presence of confirmed Alzheimer's disease neuropathology.
Alzheimer's disease is a progressive and fatal disease that in its early symptomatic stages affects 6-7.5 million Americans.
The trial enrolled 1,736 participants, across eight countries, selected based on cognitive assessments in conjunction with amyloid plaque imaging and tau staging by positron emission tomography (PET) imaging.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.